Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

David Sacks, the Trump administration’s A.I. and crypto czar, has helped formulate policies that aid his Silicon Valley friends and many of his own tech investments. Credit...Mark Harris Supported by ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...